Marcin Okrój Selected Research

Marcin Okrój Research Topics

Disease

7	Neoplasms (Cancer) 03/2022 - 01/2006
4	Infections 01/2019 - 01/2006
3	Melanoma (Melanoma, Malignant) 01/2006 - 01/2003
2	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2020 - 01/2020
2	Lupus Nephritis 01/2019 - 12/2017
1	Spontaneous Abortion (Miscarriage) 01/2022
1	COVID-19 01/2021
1	Nephrotic Syndrome (Syndrome, Nephrotic) 01/2021
1	Lymphoma (Lymphomas) 01/2020
1	Acquired Partial Lipodystrophy 01/2019
1	Kidney Diseases (Kidney Disease) 01/2019
1	Membranoproliferative Glomerulonephritis (Membranoproliferative Glomerulonephritis, Type II) 01/2019
1	Proteinuria 01/2019
1	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2019
1	Lung Neoplasms (Lung Cancer) 01/2018
1	Atypical Hemolytic Uremic Syndrome 01/2018
1	Inflammation (Inflammations) 01/2018
1	Rheumatic Diseases (Rheumatism) 11/2016
1	Systemic Scleroderma (Systemic Sclerosis) 11/2016
1	Glomerulonephritis 01/2016
1	Opportunistic Infections (Opportunistic Infection) 01/2006
1	Necrosis 01/2006
1	Neoplasm Metastasis (Metastasis) 01/2003

Drug/Important Bio-Agent (IBA)

11	Complement System Proteins (Complement)IBA 03/2022 - 01/2016
4	Rituximab (Mabthera)FDA Link 03/2022 - 04/2019
4	Monoclonal AntibodiesIBA 01/2020 - 04/2016
3	Pharmaceutical PreparationsIBA 03/2022 - 01/2006
3	ofatumumab FDA Link 03/2022 - 04/2019
3	AutoantibodiesIBA 01/2019 - 01/2016
2	AntibodiesIBA 01/2020 - 01/2018
2	Complement Inactivating AgentsIBA 04/2019 - 04/2016
2	Antigen-Antibody Complex (Immune Complex)IBA 01/2019 - 01/2019
2	Peptides (Polypeptides)IBA 01/2006 - 01/2003
2	O-(Chloroacetylcarbamoyl)fumagillol (TNP 470)IBA 01/2006 - 09/2005
1	VaccinesIBA 01/2022
1	AnaphylatoxinsIBA 01/2021
1	daratumumabIBA 01/2021
1	obinutuzumabIBA 01/2021
1	Complement C5a (Complement 5a)IBA 01/2021
1	Alemtuzumab (Campath)FDA Link 01/2020
1	fluorexon (calcein)IBA 01/2020
1	AntigensIBA 01/2020
1	DNA (Deoxyribonucleic Acid)IBA 01/2019
1	VitronectinIBA 01/2018
1	anti-dsDNA autoantibodyIBA 12/2017
1	Biomarkers (Surrogate Marker)IBA 11/2016
1	Opsonin Proteins (Opsonins)IBA 04/2016
1	EpitopesIBA 04/2016
1	complement 4 nephritic factorIBA 01/2016
1	Free RadicalsIBA 01/2006
1	Antifungal AgentsIBA 01/2006
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2006
1	temporinIBA 01/2006
1	pexigananIBA 01/2006
1	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2006
1	Angiogenesis Inducing Agents (Angiogenesis Factor)IBA 01/2006
1	OmigananIBA 01/2006
1	Uperoleia mjobergii uperin 3.6 peptideIBA 01/2006
1	antimicrobial peptide IB-367 (iseganan)IBA 01/2006
1	fumagillinIBA 09/2005
1	Biological ProductsIBA 01/2003
1	Fibronectins (Fibronectin)IBA 01/2003
1	poly (arginyl-glycyl-aspartic acid)IBA 01/2003

Therapy/Procedure

2	Therapeutics 08/2021 - 01/2020
1	Immunotherapy 01/2020